

10/574278

VERIFICATION OF A TRANSLATION

IP20 Rec'd PCT/JP/10-31 MAR 2006

I, the below named translator, hereby declare that:

My name and post office address are as stated below:

That I am knowledgeable in the English language and in the language in which the below identified international application was filed, and that I believe the English translation of the international application No. PCT/JP2004/015305 is a true and complete translation of the above identified international application as filed.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

March 16, 2006

Full name of the translator Hiromichi KAKEHI

Signature of the translator



Post Office Address Kitahama TNK Building 7-1, Dosho-machi

1-chome, Chuo-ku, Osaka-shi, Osaka 541-0045

Japan

-1-

# DESCRIPTION


PENICILLIN CRYSTALS AND PROCESS FOR PRODUCING THE SAME

## TECHNICAL FIELD

5           The present invention relates to penicillin crystals and a process for producing the same.

## BACKGROUND OF THE INVENTION

Formula (1):




10

Tazobactam, which is represented by Formula (1) given above, exhibits very weak antibacterial activity, and it is therefore not used alone as an antibacterial agent. However, it irreversibly binds to various  $\beta$ -lactamases produced by microorganisms and exhibits an ability to inhibit  $\beta$ -lactamase activities. Hence, tazobactam is used in combination with various existing antibacterial agents that are inactivated by  $\beta$ -lactamases, allowing such antibacterial agents to exhibit their inherent antibacterial activity against  $\beta$ -lactamase-producing microorganisms (Katsuji SAKAI, *Recent Antibiotics Manual*, 10<sup>th</sup> ed., page 113).

15

20

2 $\beta$ -chloromethyl-2 $\alpha$ -methylpenam-3 $\alpha$ -carboxylic acid benzhydryl ester (hereinafter sometimes referred to as "CMPB") has a chemical structure represented by Formula (2):




wherein Ph is phenyl.

As shown in the reaction scheme below, tazobactam is produced from CMPB via triazolylation at the 2'- position, oxidization at the 1- position and

deesterification at the 3- position. Therefore, CMPB is

Reaction Scheme:



CMPB is usually produced, for example, according

to a process in which 2-oxo-4-(benzothiazol-2-yl)dithio- $\alpha$ -isopropenyl-1-azetidine acetic acid benzhydryl ester is reacted with a hydrohalogenic acid in a solvent in the presence of a nitrous acid salt and/or a nitrous acid ester (see Japanese Patent No. 2602669), or according to a process in which 2-oxo-4-(benzothiazol-2-yl)dithio- $\alpha$ -isopropenyl-1-azetidine acetic acid benzhydryl ester is reacted with a copper chloride in a solvent (see U.S. Patent No. 4,496,484)

10 CMPB obtained according to the processes disclosed in Japanese Patent No. 2602669 and U.S. Patent No. 4,496,484 is in the form of an oil (see Comparative Examples 1 and 2 below). Such CMPB is problematic in that it is unstable due to the presence of a halogen atom,  
15 which is easily eliminated, in the molecule. For example, once stored at ordinary temperatures (room temperature), CMPB as obtained according to the aforementioned processes undergoes degradation in a relatively short period of time so that the quality thereof is severely deteriorated.

20 A high degree of stability is desired in intermediates for synthesizing pharmaceuticals such that the intermediates do not undergo decomposition, deterioration, etc., under mild and economical conditions as in storage at ordinary temperatures, enabling their  
25 initial qualities to be maintained over a long period of

time. Accordingly, a high degree of stability is desired in CMPB as well.

#### DISCLOSURE OF THE INVENTION

5           An object of the present invention is to provide CMPB crystals of excellent stability.

          The inventors conducted extensive research to solve the problem described above and, as a result, succeeded in recovering CMPB crystals of excellent  
10   stability, by concentrating a CMPB-containing solution, subjecting the thus-obtained concentrate to column chromatography, concentrating the CMPB-containing fraction thus obtained, and treating the CMPB-containing concentrate with specific solvents. The present invention  
15   has been accomplished based on these findings.

          The present invention provides the crystals and process as described in the following items 1 to 4:

          1. Crystals of 2 $\beta$ -chloromethyl-2 $\alpha$ -methylpenam-3 $\alpha$ -carboxylic acid benzhydryl ester.

20           2. Crystals according to Item 1 that have peaks at the following interplanar spacings in the X-ray powder diffraction pattern obtained by a copper radiation of  $\lambda=1.5418$  Å through a monochromator:

d (Interplanar spacings)

25           7.27-8.16

5.36-5.93

4.44-4.92

3.64-4.37

3. Crystals according to Item 1 that have peaks  
5 at the following interplanar spacings in the X-ray powder  
diffraction pattern obtained by a copper radiation of  
 $\lambda=1.5418 \text{ \AA}$  through a monochromator:

d (Interplanar spacings)

7.2787-8.1577

10 5.3646-5.9292

4.4430-4.9106

3.6423-4.3602

4. A process for producing crystals of 2 $\beta$ -  
chloromethyl-2 $\alpha$ -methylpenam-3 $\alpha$ -carboxylic acid benzhydryl  
15 ester comprising the steps of:

(A) concentrating a solution containing 2 $\beta$ -  
chloromethyl-2 $\alpha$ -methylpenam-3 $\alpha$ -carboxylic acid benzhydryl  
ester (CMPB);

(B) subjecting the thus-obtained concentrate to  
20 column chromatography;

(C) concentrating a CMPB-containing fraction;  
and

(D) dissolving the thus-obtained CMPB-containing  
concentrate in an ether solvent and adding a hydrocarbon  
25 solvent to the resulting solution to precipitate CMPB

crystals.

The CMPB crystals of the present invention can be produced by carrying out, for example, Steps (A) to (D)  
5 below:

Step A

CMPB-containing solutions usable in this step are known and include CMPB-containing reaction solutions  
10 obtained according to the processes disclosed in, for example, Japanese Patent No. 2602669 and U.S. Patent No. 4,496,484.

CMPB-containing solutions can be concentrated according to known concentration techniques. An example  
15 of such a concentration technique is concentration under reduced pressure. The temperature during concentration should not exceed 50°C, and it is preferably from -10 to 30°C, and more preferably from 15 to 25°C.

The extent of concentrating CMPB-containing  
20 solutions is such that purification by column chromatography in Step B is not adversely affected.

Prior to Step A, it is preferable to remove insoluble materials from the CMPB-containing solution by filtration.

Step B

The concentrate obtained in Step A is purified by column chromatography.

Known column chromatography, e.g., silica gel  
5 column chromatography, can be used in this step.

Silica gel is not limited, and a variety of commercially available products such as Wakogel C-200 (manufactured by Wako Pure Chemical Industries, Ltd.), Silicagel 60 (manufactured by Merck, Ltd.) are usable.

10 Although the amount of silica gel varies depending on the diameter of the column to be used and other such factors, it is usually from about 2 to about 200 parts by weight and preferably from about 10 to about 100 parts by weight per part by weight of CMPB to be  
15 treated.

Developing solvents are those that are usually used in column chromatography, and include, benzene, toluene, and like aromatic hydrocarbons; methyl acetate, ethyl acetate, and like esters; acetone, methyl ethyl  
20 ketone, di-n-butyl ketone, and like ketones; acetonitrile; dichloromethane, dichloroethane, chloroform, carbon tetrachloride, and like halogenated hydrocarbons; diethyl ether, dioxane, tetrahydrofuran, and like ethers; *n*-hexane, and like aliphatic hydrocarbons, cyclohexane, and like  
25 alicyclic hydrocarbons, etc. Such solvents can be used



singly, or two or more of such solvents may be combined in a suitable proportion for use.

A preferable example of developing solvents is a mixture of ethyl acetate and benzene. The volume ratio of ethyl acetate/benzene in the mixture is usually from about 1/10 to about 1/30 and preferably from about 1/15 to about 1/25.

The amount of developing solvent can be suitably selected according to the amount of CMPB to be treated, the amount of silica gel to be used, the type of developing solvent to be used, etc.

CMPB-containing fractions obtained in this step are collected and used in the following Step C.

#### 15 Step C

The CMPB-containing fraction obtained in Step B can be concentrated according to known concentration techniques. An example of such a concentration technique is concentration under reduced pressure. The temperature during concentration should not exceed 50°C, and it is preferably from -10 to 30°C, and more preferably from 15 to 25°C.

Although it is desirable to remove as much of solvents contained in the CMPB-containing fraction as possible, it is sufficient that the CMPB-containing

fraction is concentrated to have a solvent content of no more than 80 vol.%, preferably no more than 60 vol.%, and more preferably no more than 50 vol.%.

5    Step D

CMPB crystals are precipitated by dissolving the CMPB-containing concentrate obtained in Step C in an ether solvent and then adding a hydrocarbon solvent thereto.

Known ether solvents that can dissolve CMPB can  
10    be used in this step. Examples of preferable ether solvents are diethyl ether, diisopropyl ether, etc. Such ether solvents can be used singly or in combination.

The amount of ether solvent is such that the CMPB-containing concentrate is fully dissolved in the  
15    ether solvent. It is usually from about 0.5 to about 5 liters and preferably from about 0.80 to about 3 liters per kg of CMPB contained in the CMPB-containing concentrate. It is preferable to use the ether solvent in a volume equal to or greater than the volume of the  
20    solvent contained in the CMPB-containing concentrate.

The temperature during dissolution of the CMPB-containing concentrate in the ether solvent is usually from about -30 to about 50°C and preferably from about -10 to about 30°C.

25    Known hydrocarbon solvents that do not readily

dissolve CMPB can be used in this step. Examples of such hydrocarbon solvents are *n*-pentane, *n*-hexane, *n*-heptane, *n*-octane and like aliphatic hydrocarbons, cyclohexane and like alicyclic hydrocarbons, etc. Among such hydrocarbon  
5 solvents, aliphatic hydrocarbons are preferable, with *n*-hexane being particularly preferable.

The amount of hydrocarbon solvent is such that CMPB is precipitated. It is usually sufficient that the hydrocarbon solvent is gradually added in a total weight  
10 from about 0.1 to about 20 times and preferably about 0.5 to about 10 times the weight of the ether solvent used.

The temperature at which the hydrocarbon solvent is added is, in view of precipitation efficiency, usually from about -30 to about 50°C and preferably from about -10  
15 to about 30°C.

CMPB crystals generated by precipitation can be separated from the ether solvent and the hydrocarbon solvent according to conventional separation techniques. Examples of such separation techniques are filtration,  
20 centrifugation, etc. Filtration can be carried out under atmospheric pressure, increased pressure, or reduced pressure.

In the process of the invention, it is preferable to perform Steps A to D successively as  
25 promptly as possible.

EFFECTS OF THE INVENTION

The CMPB crystals of the present invention are stable despite the presence of a halogen atom, which is easily eliminated, in the molecule and do not undergo decomposition, deterioration, etc., after room temperature storage longer than one month, enabling the initial quality to be maintained.

Moreover, even when the CMPB crystals of the invention are dissolved in an organic solvent, e.g., dichloromethane, CMPB is extremely stable over a long period of time, not substantially undergoing decomposition. Hence, the triazolylation at the 2'- position, as shown in the reaction scheme above, of the crystalline CMPB of the invention can give the desired triazolylated compound in an enhanced yield.

Therefore, the crystalline CMPB of the invention can be suitably used as an intermediate for synthesizing pharmaceuticals such as tazobactam.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is the x-ray powder diffraction pattern of the foamy material obtained in Reference Example 1.

Figure 2 is the x-ray powder diffraction pattern of the CMPB crystals obtained in Example 1.

BEST MODE FOR CARRYING OUT THE INVENTION

An example, a reference example, comparative

examples and test examples are given below to describe the invention in more detail.

#### Reference Example 1

To a dichloromethane solution of 45.8 g of 2-oxo-  
5 4-(benzothiazol-2-yl)dithio- $\alpha$ -isopropenyl-1-azetidine  
acetic acid benzhydryl ester (240 ml) were added 48.6 ml  
of a 35% hydrochloric acid and 48.5 ml of 5°C water while  
ice cooling. An 36% aqueous sodium nitrite solution (18  
ml) was then added dropwise over 30 minutes. The mixture  
10 was then stirred for 1 hour while ice cooling, the  
precipitate was filtered off, and the organic layer of the  
filtrate was separated. The organic layer was washed twice  
with cold water, dried over magnesium sulfate, and  
concentrated under reduced pressure, thereby giving 40 g of  
15 a foamy material.

A  $^1\text{H}$ -NMR spectral analysis revealed that the  
foamy material was of CMPB. A clear X-ray powder  
diffraction pattern was not obtained by copper radiation  
of  $\lambda=1.5418 \text{ \AA}$  through a monochromator, thereby revealing  
20 that the foamy material was amorphous CMPB.

Figure 1 shows the x-ray powdery diffraction  
pattern of the foamy material obtained above.

#### Example 1

25 Step A:

To a dichloromethane solution of 45.8 g of 2-oxo-4-(benzothiazol-2-yl)dithio- $\alpha$ -isopropenyl-1-azetidine acetic acid benzhydryl ester (240 ml) were added 48.6 ml of a 35% hydrochloric acid and 48.5 ml of 5°C water while  
5 ice cooling. A 36% aqueous sodium nitrite solution (18 ml) was then added dropwise over 30 minutes. The mixture was then stirred for 1 hour while ice cooling, the precipitate was filtered off, and the organic layer of the filtrate was separated. The organic layer was washed twice with cold  
10 water, dried over magnesium sulfate, and concentrated under reduced pressure until the amount of dichloromethane in the organic layer was 40 ml.

Step B:

The concentrate thus obtained was subjected to  
15 silica gel chromatography (filler: Wakogel C-200, 1 kg, developing solvent: benzene/ethyl acetate = 20/1 by volume) to obtain CMPB-containing fractions. CMPB-containing fractions obtained were collected.

Step C:

20 The collected CMPB-containing fraction was promptly concentrated at 20°C under reduced pressure until the amount of solvent contained in the concentrate decreased to about 10 vol.%.

Step D:

25 To the CMPB-containing concentrate thus obtained

was added 50 ml of diethyl ether at 20°C to give a solution. To this solution was gradually added 100 ml of *n*-hexane, thereby precipitating crystals.

The precipitated crystals were recovered by  
5 reduced-pressure filtration, washed with *n*-hexane and dried under reduced pressure at room temperature. The yield was 16.4 g.

A <sup>1</sup>H-NMR spectral analysis verified that the crystals were of CMPB.

10 <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>, δ ppm): 1.33 (s, 3H), 3.12 (dd, *J* = 2 Hz, 16 Hz, 1H), 3.60 (s, 1H), 3.61 (dd, *J* = 4 Hz, 16 Hz, 1H), 5.13 (s, 1H), 5.26, 5.34 (ABq, *J* = 13 Hz, 2H), 5.41 (dd, *J* = 2 Hz, 4 Hz, 1H), 7.25-7.40 (m, 10H)

A clear X-ray powder diffraction pattern of the  
15 crystals was obtained by copper radiation of λ=1.5418 Å through a monochromator as shown below:

	d (Interplanar spacings)	Relative intensities (I/I <sub>0</sub> )
	9.461	0.21
	7.769	0.50
20	7.662	0.51
	6.506	0.35
	5.647	1.00
	5.248	0.29
	4.761	0.30
25	4.677	0.40

	4.358	0.25
	4.275	0.28
	4.153	0.51
	3.907	0.19
5	3.834	0.36
	3.448	0.26
	3.200	0.19

Figure 2 shows the X-ray powder diffraction pattern of the crystals.

10

#### Comparative Example 1

To a foamy material as obtained in Reference Example 1 (20 g) was added acetone to dissolve it in the acetone. Insoluble materials were removed by filtration.

15 The filtrate was concentrated, and 25 ml diethyl ether was added to the concentrate to attempt precipitation.

However, precipitation of solids was not observed and the solution stayed homogenous. To the solution was further gradually added *n*-hexane, but  
20 precipitation of solids was not observed and an oily material eventually appeared.

#### Comparative Example 2

A foamy material as obtained in Reference  
25 Example 1 (40 g) was dissolved in 40 ml dichloromethane



and subjected to silica gel chromatography (filler: Wakogel C-200, 1 kg, developing solvent: benzene/ethyl acetate = 20/1 by volume). The CMPB-containing fraction was promptly concentrated at 20°C under reduced pressure, 5 thereby giving an oily material.

A <sup>1</sup>H-NMR spectral analysis revealed that the oily material was of CMPB.

#### Test Example 1

10 Five grams of the crystalline CMPB obtained in Example 1 (purity: 100%) and 5 g of the amorphous CMPB obtained in Reference Example 1 (purity: 99.2%) were placed in respective test tubes. These test tubes were sealed and stored at room temperature (20 to 30°C) for 1 15 month. The respective purities of the CMPB samples were then determined using liquid chromatography.

The results revealed that the purity of the crystalline CMPB of Example 1 was 95%. The crystalline CMPB of Example 1 did not undergo significant 20 decomposition, deterioration, etc., maintaining its initial quality. On the other hand, the purity of the amorphous CMPB of Reference Example 1 was 67%. The amorphous CMPB of Reference Example 1 lacked stability.

#### 25 Test Example 2

One gram of crystalline CMPB (purity: 97%) prepared by storing the crystalline CMPB of Example 1 for 20 days at room temperature (about 25°C) and 1.244 g of amorphous CMPB (purity: 78%) prepared by storing the  
5 amorphous CMPB of Reference Example 1 for 20 days at room temperature (about 25°C) were used as test samples. Each sample was placed in flasks and 10 ml dichloromethane was added to dissolve the sample. These flasks were sealed. The dichloromethane solutions of CMPB samples were stirred  
10 at room temperature (about 25°C) and, after 3.5 hours and after 5 hours, subjected to liquid chromatography to measure the amounts of CMPB remaining in the solutions. The amounts of the remaining CMPB were compared with the amount of CMPB in the crystalline CMPB sample or the  
15 amount of CMPB in the amorphous CMPB sample, which were measured prior to the test.

The results revealed that the amounts of the CMPB in the dichloromethane solution of crystalline CMPB sample after 3.5 hours and after 5 hours were exactly the  
20 same as the initial amount of CMPB in the crystalline CMPB, showing that the CMPB did not decompose in dichloromethane. On the other hand, the amounts of the CMPB in the dichloromethane solution of amorphous CMPB sample after 3.5 and 6 hours were 86.8% and 63.4%, respectively, of the  
25 initial amount of CMPB in the amorphous CMPB, showing that

-18-

the CMPB in dichloromethane gradually decomposed.